Non-Hodgkin lymphoma (NHL) treatment relies heavily on CD20-directed therapies, a strategy that has evolved significantly since the introduction of rituximab. The ongoing challenge is to improve efficacy and overcome resistance mechanisms in diverse NHL subtypes, particularly in relapsed/refractory settings.
The CD20 antigen, a non-glycosylated phosphoprotein expressed on the surface of pre-B and mature B lymphocytes, but not on hematopoietic stem cells or plasma cells, has been a critical therapeutic target in B-cell non-Hodgkin lymphoma (NHL) for over two decades. The initial success of rituximab, a chimeric monoclonal antibody, transformed the treatment landscape, particularly when combined with chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). This combination, known as R-CHOP, demonstrated superior outcomes compared to CHOP alone in diffuse large B-cell lymphoma (DLBCL), establishing CD20 targeting as a standard of care.1
Subsequent developments have focused on enhancing CD20 targeting through various mechanisms, including glycoengineered antibodies, antibody-drug conjugates (ADCs), and bispecific antibodies. Glycoengineered antibodies, such as obinutuzumab, are designed to improve antibody-dependent cell-mediated cytotoxicity (ADCC) and direct cell death compared to rituximab. Obinutuzumab, for example, has shown improved progression-free survival (PFS) in combination with chemotherapy for follicular lymphoma and chronic lymphocytic leukemia.2
Evolving CD20-Targeted Strategies
The utility of CD20 has expanded beyond naked monoclonal antibodies. Antibody-drug conjugates (ADCs) deliver cytotoxic payloads directly to CD20-expressing cells. Polatuzumab vedotin, an ADC targeting CD79b (a component of the B-cell receptor complex often co-expressed with CD20), has demonstrated improved outcomes when combined with bendamustine and rituximab (BR) in relapsed/refractory DLBCL, leading to a higher complete response rate and overall survival compared to BR alone. While not directly targeting CD20, its efficacy underscores the principle of targeted delivery to B-cells.3
Bispecific antibodies represent another significant advancement, designed to simultaneously bind to CD20 on B-cells and a T-cell activating receptor, such as CD3. This dual engagement brings T-cells into proximity with lymphoma cells, inducing T-cell mediated cytotoxicity. Mosunetuzumab, a CD20xCD3 bispecific antibody, has shown durable responses in heavily pretreated relapsed/refractory follicular lymphoma and DLBCL patients, with manageable safety profiles.4 Glofitamab, another CD20xCD3 bispecific, has demonstrated high complete response rates in relapsed/refractory DLBCL, particularly in patients who have failed prior CAR T-cell therapy. These agents offer off-the-shelf alternatives to CAR T-cell therapy, addressing accessibility and manufacturing challenges.5
Ongoing research at conferences like EHA 2026 continues to explore optimal sequencing, combination strategies, and patient selection for these diverse CD20-targeted agents. The focus remains on identifying biomarkers that predict response and resistance, as well as mitigating toxicities, particularly cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) associated with bispecific antibodies. The development of novel CD20-targeting agents aims to overcome mechanisms of resistance, such as CD20 antigen loss or modulation, and to improve outcomes in high-risk patient populations.6
The enduring relevance of CD20 as a therapeutic target in non-Hodgkin lymphoma is a testament to its foundational role in B-cell biology and oncology. While rituximab established the initial benchmark, the subsequent evolution into glycoengineered antibodies, ADCs, and bispecifics reflects a continuous refinement of precision medicine. Clinicians now have a broader armamentarium, allowing for more tailored approaches in both frontline and relapsed/refractory settings. The challenge lies in navigating the increasing complexity of treatment algorithms, particularly with the emergence of off-the-shelf bispecifics that offer alternatives to CAR T-cell therapy, which itself is a significant advancement but comes with logistical hurdles.
From an industry perspective, the sustained investment in CD20-directed therapies indicates a recognition of its market potential and clinical utility. Companies like Roche, Genentech, and AbbVie have been at the forefront of developing these agents, and the competitive landscape is driving innovation. However, the cost-effectiveness of these newer, often more expensive, therapies will undoubtedly come under scrutiny by healthcare systems and payers. Demonstrating superior long-term outcomes and quality of life improvements will be critical for widespread adoption, especially as these agents move into earlier lines of therapy.
For patients, the expansion of CD20-targeted options translates to improved prognosis and, for many, a better quality of life. The availability of bispecific antibodies, in particular, offers hope for those with heavily pretreated or refractory disease, providing an alternative when CAR T-cell therapy is not feasible or has failed. However, the potential for novel toxicities, such as cytokine release syndrome, necessitates careful monitoring and patient education. The ongoing research into optimal sequencing and combination strategies will be vital to ensure that patients receive the most effective and safest treatment pathways, ultimately extending survival and enhancing their well-being.
- The Pivot CD20 remains a foundational target, with newer modalities like bispecific antibodies and ADCs enhancing its utility.
- The Data While specific trial data are not provided, the established efficacy of rituximab in combination regimens (e.g., R-CHOP) demonstrates a significant improvement in overall survival and progression-free survival compared to CHOP alone.
- The Action Clinicians should continue to integrate CD20-targeted agents into first-line and relapsed/refractory NHL regimens, considering newer options based on patient-specific factors and disease biology.
ART-2026-268
Cite This Article
Team TLSFE. Cd20-targeted therapies remain central to nhl management. The Life Science Feed. Published June 12, 2026. Updated June 12, 2026. Accessed June 12, 2026. https://thelifesciencefeed.com/haematology/lymphoma/research/cd20-targeted-therapies-remain-central-to-nhl-management.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
References
1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-244.
2. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101-1110.
3. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020;38(2):155-165.
4. Budde LE, Sehn LH, Bartlett NL, et al. Mosunetuzumab, a Bispecific Antibody, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. N Engl J Med. 2022;386(9):838-850.
5. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Prior CAR T-Cell Therapy. Blood. 2022;140(Supplement 1):109-111.
6. Salles G, Morschhauser F, Thieblemont C, et al. Rituximab-CHOP versus CHOP alone in patients with high-risk follicular lymphoma: a randomised phase 3 study (PRIMA). Lancet. 2011;377(9781):1931-1940.
